{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:56:19Z","timestamp":1793498179199,"version":"4.5.0"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The feasibility of endovascular treatment (EVT) for Trans-Atlantic Inter-Society Consensus (TASC) II C and D femoropopliteal artery lesions has been described, but no prospective study has performed a long-term follow-up. The aim of this study was to report the long-term results of nitinol stents (NS) for the treatment of long femoropopliteal lesions. Materials and Methods: A single-center prospective, randomized controlled trial (RCT) comparing EVT with NS and vein bypass surgery was previously performed. The EVT group\u2019s follow-up was extended and separately analyzed with primary patency as the primary endpoint. The secondary endpoints were technical success, secondary patency, reinterventions, limb salvage, survival, complications, and clinical improvement. Results: Between 2016 and 2020, 109 limbs in 103 patients were included. A total of 48 TASC II C and 61 TASC II D lesions with a mean lesion length of 264 mm were reported. In 53% of limbs, the indication for treatment was chronic limb-threatening ischemia. The median follow-up was 45 months. Technical success was achieved in 88% of cases, despite 23% of the lesions being longer than 30 cm (retrograde popliteal access in 22%). At four-year follow-up, primary patency, secondary patency, and freedom from target lesion revascularizations were 35%, 48%, and 58%, respectively. Limb salvage and survival were 90% and 80% at 4 years. Clinical improvement of at least one Rutherford category at the end of follow-up was achieved in 83% of limbs. Conclusions: This study reports the longest follow-up of endovascular treatment with nitinol stents in femoropopliteal TASC II C and D lesions. The results emphasize the feasibility of an endovascular-first strategy, even in lesions beyond 30 cm in length, and clarify its acceptable long-term durability and good clinical outcomes. Large multicenter RCTs with mid- and long-term follow-up are needed to investigate the role of different endovascular techniques in long femoropopliteal lesions.<\/jats:p>","DOI":"10.3390\/medicina58091225","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T22:33:01Z","timestamp":1662503581000},"page":"1225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Results of Endovascular Treatment with Nitinol Stents for Femoropopliteal TASC II C and D Lesions"],"prefix":"10.3390","volume":"58","author":[{"given":"Michaela","family":"Kluckner","sequence":"first","affiliation":[{"name":"Department of Vascular Surgery, Medical University Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Nierlich","sequence":"additional","affiliation":[{"name":"Chirurgie Nierlich, Vienna Private Hospital, A-1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7696-1479","authenticated-orcid":false,"given":"Wolfgang","family":"Hitzl","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Optometry, Paracelsus Medical University Salzburg, A-5020 Salzburg, Austria"},{"name":"Research and Innovation Management, Paracelsus Medical University, A-5020 Salzburg, Austria"},{"name":"Research Program Experimental Ophthalmology and Glaucoma Research, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3373-8194","authenticated-orcid":false,"given":"Thomas","family":"Aschacher","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Clinic Floridsdorf and Karl Landsteiner Institute for Cardio-Vascular Research, A-1210 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0533-3387","authenticated-orcid":false,"given":"Alexandra","family":"Gratl","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Medical University Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Wipper","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Medical University Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3506-0594","authenticated-orcid":false,"given":"Manuela","family":"Aspalter","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Vascular and Endovascular Surgery, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Moussalli","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Vascular and Endovascular Surgery, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Linni","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Vascular and Endovascular Surgery, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7200-4145","authenticated-orcid":false,"given":"Florian K.","family":"Enzmann","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Medical University Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.300.2.197","article-title":"Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis","volume":"300","author":"Fowkes","year":"2008","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jakubiak, G.K., Pawlas, N., Cieslar, G., and Stanek, A. (2020). Chronic Lower Extremity Ischemia and Its Association with the Frailty Syndrome in Patients with Diabetes. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17249339"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jakubiak, G.K., Pawlas, N., Cieslar, G., and Stanek, A. (2021). Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph182211970"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1358863X07079823","article-title":"Current state of endovascular treatment of femoro-popliteal artery disease","volume":"12","author":"Zeller","year":"2007","journal-title":"Vasc. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2006.09.024","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"33","author":"Norgren","year":"2007","journal-title":"Eur J. Vasc. Endovasc. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejvs.2017.07.018","article-title":"Editor\u2019s Choice\u20142017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)","volume":"55","author":"Aboyans","year":"2018","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0140-6736(05)67704-5","article-title":"Bypass versus angioplasty in severe ischaemia of the leg (BASIL): Multicentre, randomised controlled trial","volume":"366","author":"Adam","year":"2005","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1583\/11-3627.1","article-title":"Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: Three-year follow-up from the RESILIENT randomized trial","volume":"19","author":"Laird","year":"2012","journal-title":"J. Endovasc. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1406235","article-title":"Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease","volume":"373","author":"Rosenfield","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial","volume":"133","author":"Dake","year":"2016","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1526602817749242","article-title":"Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial","volume":"25","author":"Laird","year":"2018","journal-title":"J. Endovasc. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Nasr, B., Gouailler, F., Marret, O., Guillou, M., Chaillou, P., Guyomarc\u2019h, B., Maurel, B., and Goueffic, Y. (2022). Treatment of Long Femoropopliteal Lesions With Self-Expanding Interwoven Nitinol Stent: 24 Month Outcomes of the STELLA-SUPERA Trial. J. Endovasc. Ther., 15266028221075227.","DOI":"10.1177\/15266028221075227"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.avsg.2016.10.058","article-title":"Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis","volume":"43","author":"Vent","year":"2017","journal-title":"Ann. Vasc. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1526602820965965","article-title":"Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: 36-Month Results of the Viabahn 25 cm Trial","volume":"28","author":"Bohme","year":"2021","journal-title":"J. Endovasc. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Enzmann, F.K., Nierlich, P., Holzenbein, T., Aspalter, M., Kluckner, M., Hitzl, W., Opperer, M., and Linni, K. (2022). Vein Bypass versus Nitinol Stent in Long Femoropopliteal Lesions: 4-Year Results of a Randomized Controlled Trial. Ann. Surg.","DOI":"10.1097\/SLA.0000000000005413"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","article-title":"Recommended standards for reports dealing with lower extremity ischemia: Revised version","volume":"26","author":"Rutherford","year":"1997","journal-title":"J. Vasc Surg"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jcin.2019.09.006","article-title":"Nitinol Stent Versus Bypass in Long Femoropopliteal Lesions: 2-Year Results of a Randomized Controlled Trial","volume":"12","author":"Enzmann","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/1526602815592206","article-title":"An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"22","author":"Jaff","year":"2015","journal-title":"J. Endovasc. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.jcin.2017.09.013","article-title":"1-Year Results of a Multicenter Randomized Controlled Trial Comparing Heparin-Bonded Endoluminal to Femoropopliteal Bypass","volume":"10","author":"Reijnen","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.avsg.2018.04.014","article-title":"Drug-Eluting Stent Shows Similar Patency Results as Prosthetic Bypass in Patients with Femoropopliteal Occlusion in a Randomized Trial","volume":"53","author":"Bjorkman","year":"2018","journal-title":"Ann. Vasc. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1526602820902014","article-title":"ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions","volume":"27","author":"Bosiers","year":"2020","journal-title":"J. Endovasc. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00270-014-1024-9","article-title":"Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: The VIASTAR trial","volume":"38","author":"Lammer","year":"2015","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejvs.2015.07.018","article-title":"Treatment of TASC C and D Femoropoliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry","volume":"50","author":"Davaine","year":"2015","journal-title":"Eur J. Vasc Endovasc. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00270-015-1175-3","article-title":"Mid-Term Outcomes of Endovascular Treatment for TASC-II D Femoropopliteal Occlusive Disease with Critical Limb Ischemia","volume":"39","year":"2016","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jcin.2017.01.028","article-title":"2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study","volume":"10","author":"Micari","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.jcin.2018.07.041","article-title":"Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I","volume":"11","author":"Xu","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jcin.2018.03.046","article-title":"1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty","volume":"11","author":"Bisdas","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.avsg.2018.06.015","article-title":"Risk Factors for Restenosis after Drug-coated Balloon Angioplasty for Complex Femoropopliteal Arterial Occlusive Disease","volume":"55","author":"Roh","year":"2019","journal-title":"Ann. Vasc. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.avsg.2014.03.033","article-title":"Primary stenting of TASC C and D femoropopliteal lesions: Results of the STELLA register at 30 months","volume":"28","author":"Davaine","year":"2014","journal-title":"Ann. Vasc. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J. Vasc. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejvs.2018.09.025","article-title":"Editor\u2019s Choice\u2014Infrainguinal Bypass Following Failed Endovascular Intervention Compared With Primary Bypass: A Systematic Review and Meta-Analysis","volume":"57","author":"Hossain","year":"2019","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jvs.2011.03.236","article-title":"Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass","volume":"54","author":"Nolan","year":"2011","journal-title":"J. Vasc. Surg."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/9\/1225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:23:51Z","timestamp":1760142231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/9\/1225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["medicina58091225"],"URL":"https:\/\/doi.org\/10.3390\/medicina58091225","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]}}}